A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Jul 30, 2026 → Jul 30, 2027
See other at-risk trials from MediLink Therapeutics (Suzhou) Co., Ltd.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jul 30, 2026 to Jul 30, 2027
    • Eligibility criteria expanded, about 32 words
    • Secondary endpoints: details revised at 1 of 16 entries
  2. Site contact updatedv4
  3. Trial status: Active, Not Recruiting to Recruiting
    • Site details revised
    v3
  4. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Start date changed from estimate of Jul 31, 2024 to Apr 23, 2024
    • Site contact updated
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a multicenter, open-label, phase 2 clinical study to evaluate the efficacy, safety and pharmacokinetics of YL202 in patients with locally advanced or metastatic breast cancer with TNBC, HR-positive, HER2-zero-expression or HER2-low-expression
Trial Details
NCT Number NCT06439771
Lead Sponsor MediLink Therapeutics (Suzhou) Co., Ltd.
Conditions
(from sponsor)		 Locally Advanced or Metastatic Breast Cancer
Related terms Breast Neoplasms
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov